Week in Review: 3SBio Rises 5% After $711 Million IPO

3SBio of Shenyang rose 5% in its first day of trading in Hong Kong following the company's $711 million IPO; Huaren Pharma, an IV drugmaker, paid $550 million to acquire Hongta Innovation Investment, which holds a 9.2% stake in Huaren; Wandong Medical, a Beijing medical imaging company, raised $147 million from seven investors, including Alibaba's Jack Ma; BioAtla of San Diego and Beijing raised $30 million from an undisclosed group of China investors; The Pharma Partners, a US-China firm, formed a partnership with Suzhou BioBAY and Legend Capital and will raise $30 million to bring four US medical device companies to China; Luqa Pharma announced a $15 million funding led by Morningside Ventures to support its China in-licensing program; Phagelux, a Shanghai anti-bacterial company, reported a $10 million fundraising; Beijing's Annoroad Gene Technology will collaborate with Illumina to develop a next-gen prenatal DNA diagnostic test for China; China is home for three of the top five global entities in terms of biotech patent filings/approvals; and Suzhou NeuPharma began a Australian Phase I clinical trial in patients with solid tumor cancers. More details.... Stock Symbols: (HK: 1530) (SHZ: 300110) (SHA: 600055) (NYSE: BABA) (NSDQ: ILMN) Share this with colleagues: // //